Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Anatomic Stage I Breast Cancer AJCC v8 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Melanoma 1Leukemia, Hairy Cell 1Carcinoma, Medullary 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pertuzumab 2Trastuzumab 2Taxes 2Paclitaxel 2High-Energy Shock Waves 2Docetaxel 2Biopsy 2trastuzumab biosimilar HLX02 1pembrolizumab 1Watchful Waiting 1Transcutaneous Electric Nerve Stimulation 1Standard of Care 1Specimen Handling 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1PF-05280014 1Ontruzant 1Ogivri 1Observation 1Minoxidil 1Methods 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Educational Status 1Early Intervention, Educational 1Disulfides 1Carboplatin 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anatomic Stage I Breast Cancer AJCC v8 × High-Energy Shock Waves × 30 days × Clear all
NCT06876714 2026-06-02

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
1,524 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

University of Washington

Phase 2 Recruiting
25 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡